Evidence map›Paper›PMID 39063311›Full record

ArticleFoods (Basel, Switzerland)2024

Comprehensive Amelioration of Metabolic Dysfunction through Administration of

Bobae Kim, Yuri Lee, Chungho Lee, Eun Sung Jung, Hyeji Kang, Wilhelm H Holzapfel

Abstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Postbiotics fromNutrients · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bobae KimBasic Research Center, HEM Pharma Inc., Pohang 37554, Republic of Korea.ORCID 0000-0003-1624-8337
Yuri LeeBasic Research Center, HEM Pharma Inc., Pohang 37554, Republic of Korea.
Chungho LeeBasic Research Center, HEM Pharma Inc., Pohang 37554, Republic of Korea.
Eun Sung JungMulti-Omics Center, HEM Pharma Inc., Suwon 16229, Republic of Korea.
Hyeji KangBasic Research Center, HEM Pharma Inc., Pohang 37554, Republic of Korea.
Wilhelm H HolzapfelBasic Research Center, HEM Pharma Inc., Pohang 37554, Republic of Korea.ORCID 0000-0002-3669-1419

Funding

HEM Pharma Inc. 20180197
6 · The paper itself

Abstract

The beneficial effects of probiotics for the improvement of metabolic disorders have been studied intensively; however, these effects are evident in a probiotic strain-specific and disease-specific manner. Thus, it is still essential to evaluate the efficacy of each strain against a target disease. Here, we present an anti-obese and anti-diabetic probiotic strain,

Indexed as

gut microbiota modulationLactobacillus plantarum APsulloc 331261 (GTB1™)metabolic dysfunctionobesityperoxisome proliferator-activated receptors (PPARs)short-chain fatty acids (SCFAs)

Identifiers

PMID39063311
PMCPMC11276112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.